Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

NCT03474094 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.

NCT NCT03474094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy
Lead sponsor
Centre Leon Berard
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 1, 2018
Completion date
December 30, 2026
Enrollment
62 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma,soft tissue